Phase Conjugation

Latest News for: phase conjugation

Edit

Investment Opportunities in Biotech Amidst Federal Rate Uncertainties (ATNM)

GetNews 22 Apr 2024

ATNM, a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, recently announced that results from the Phase 3 SIERRA trial of Iomab-B were presented in ...

Edit

Otitis Media Market Size in the 7MM is expected to grow by 2032 | DelveInsight

GetNews 16 Apr 2024

Merck Sharp & Dohme LLC announced a study of phase 3 clinical trials for V114 ... Currently, the drug is in Phase III stage of clinical trial evaluation for the treatment of Acute Otitis Media, and has been approved in Europe.

Edit

AIM Vaccine Announces 2023 Annual Results

The Arabian Post 30 Mar 2024

During the reporting period, the full course of vaccination in Phase III clinical trial of 13-valent pneumonia conjugate vaccine (PCV13) was completed, and we have submitted the pre-application for ...

Edit

Vincerx Pharma Reports Fourth Quarter And Full Year 2023 Financial Results And Corporate Update

MENA FN 29 Mar 2024

(MENAFN - GlobeNewsWire - Nasdaq) VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual ... .

Edit

Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty

Pharmiweb 19 Mar 2024

... payloads and first-in-class Amanitin-based Antibody Conjugate pipeline, including lead candidate HDP-101 which is currently progressing in a Phase I/IIa study for the treatment of multiple myeloma.

Edit

Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with ...

Hastings Tribune 12 Mar 2024

PFE) today announced that a Phase 3 study of the antibody-drug conjugate ADCETRIS ® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with ...

Edit

Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024

Pharmiweb 06 Mar 2024

HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its Phase I clinical trial with ATAC candidate HDP-101 as well ...

Edit

Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual ...

The Eagle-Tribune 05 Mar 2024

Vincerx’s diverse pipeline consists of the next-generation antibody-drug conjugate, VIP943, in Phase 1; small molecule-drug conjugate, VIP236, in Phase 1; preclinical antibody-drug conjugate, VIP924; ...

Edit

Global Bicycle Toxin Conjugates Clinical Trials Insight 2024 - Bicycle Therapeutics Emerges as a Trailblazer, ...

The Huntsville Item 04 Mar 2024

The "Global Bicycle Toxin Conjugates Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering ... 5.4 By Phase ... Global Bicyclic Toxin Conjugates Clinical Pipeline by Company, Indication & Phase.

Edit

AIM Vaccine Enters the Period of Explosive Growth in Major Single Products

Tyler Morning Telegraph 04 Mar 2024

The Company has initiated Phase II clinical trials for its Tetravalent meningococcal conjugate vaccine (MCV4), while the clinical trials for the Group's diphtheria, tetanus and acellular pertussis – HIB combined vaccine is also progressing rapidly.

Edit

Hyper-spectral-resolution stimulated Raman spectroscopy with amplified fs pulse bursts

Phys Dot Org 04 Mar 2024

They utilize amplified and offset-phase controlled femtosecond-pulse bursts to achieve ... In a well-designed optical parametric amplifier, the phases of the signal and idler pulses can be conjugated.

Edit

Over 20 Presentations on Alluminox Treatment (Photoimmunotherapy) at International Conferences in 2023

The Eagle-Tribune 01 Mar 2024

Promising early evaluation data on safety and efficacy were observed in the Phase 1b/2 clinical trial (ASP-1929-181 study / ClinicalTrials.gov Identifier ... Data from the Phase 1b/2 open-label study ASP-1929-181 (Abstract #.

Edit

Antibody Drug Conjugate Competitie Landscape Report 2023

GetNews 28 Feb 2024

It covers the Antibody Drug Conjugate pipeline therapeutics assessment by product type, stage, route of administration, and molecule type ... Unicancer announced a drug which is named DS-8201a in the clinical trials of phase 2.

Edit

G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational ...

The Eagle-Tribune 28 Feb 2024

(See February 12, 2024 press release here )Initial Efficacy Results from Ongoing Phase 2 Antibody-Drug Conjugate (ADC) Trial Suggest Improved Overall Survival (OS) Among Patients Receiving Trilaciclib in Combination with a TROP2 ADC.

Edit

Pyxis Oncology Shares Up 21% in Premarket Trading on $50M Fundraise

Market Watch 27 Feb 2024

... new money to continue the development of its lead antibody drug conjugate therapeutic candidate, PYX-201, which is currently being evaluated in a phase-1 study for solid tumors.